American Regent has issued a voluntary, nationwide recall for three specific lots of its Epinephrine Injection, USP. The decision follows reports of cracked and leaking vials, which forced the manufacturer to conclude that the product no longer meets safety standards for sterility. The recall, confirmed by the U.S. Food and Drug Administration, warns that compromised packaging risks contamination of the medication.
Investigation Findings and Contamination Risks
The company’s internal investigation identified the presence of particulate matter within the vials. Experts found fragments of nylon, cellulosic, acrylic, polyethylene, and glass. Any intravenous injection containing such particles creates a severe health risk. These foreign materials can block blood vessels and restrict flow to vital organs. Such blockages may lead to pulmonary embolism, permanent organ damage, or death. The particles also trigger local vein irritation and inflammation.
Cracked or leaking containers further compound the danger. Once the vial integrity is lost, the contents are no longer sterile. This leaves patients vulnerable to infections or adverse reactions. While the firm reported no adverse events as of September 3, 2026, the potential for harm remains significant given the critical nature of epinephrine in emergency settings.
Product Identification and Recall Scope
The affected product is the Epinephrine Injection, USP 30 mg/ 30 mL (1 mg/mL) multi-dose vial, identified by NDC number 0517-3030-01. Three specific lots are subject to this recall. Lot 25128L1C0, which expires in August 2026, was distributed between September 4, 2025, and December 18, 2025. Lot 25280L1C0, expiring in October 2026, reached the market from December 16, 2025, to April 17, 2026. Finally, lot 26108L1C0, set to expire in July 2027, was distributed between June 15, 2026, and July 31, 2026. These batches were released to healthcare providers and facilities across the United States.
Medical Utility and Patient Instructions
Epinephrine serves as a first-line treatment for anaphylaxis caused by severe allergic reactions to insect stings, foods, drugs, or environmental allergens. Clinicians also use the injection to maintain mean arterial blood pressure in adults suffering from septic shock. Because of its use in life-or-death scenarios, the sterility of every dose is paramount. If a patient or caregiver possesses a vial from these lots, they must stop using it immediately. American Regent is currently coordinating with distributors to manage the return or replacement of the product. Questions regarding specific lots or product quality should be directed to the American Regent customer service or pharmacovigilance departments.
Pharmaceutical companies operate under strict cGMP regulations to prevent exactly these types of mechanical and sterility failures. Historically, particulate matter in injectables has led to some of the largest medical product recalls in industry history. Hospitals and pharmacies often maintain inventory controls to identify and isolate these batches during the distribution cycle. The current recall serves as a reminder of the fragility of the medical supply chain.